Laboratorios Rubió, a Spanish pharmaceutical company that manufactures and markets Dolquine, a hydroxychloroquine-based medicine that is being used in the treatment of COVID-19, has announced that it has the capacity to triple its production to respond to the needs of the coronavirus.
The laboratory has reported in a statement that it has been made available to the Spanish Agency for Medicines and Health Products (Aemps) to be able to supply the drug based on its current production capacities.
